Background: Elevated high-sensitive C-reactive protein is a powerful independent predictor of cardiovascular events. However, there are scant data on its impact on midterm or long-term outcomes of coronary artery bypass grafting.
Method: We analyzed data of 2863 patients who underwent coronary artery bypass in 2006–2007. Early endpoints were hospital mortality and major morbidity. Midterm endpoints were overall mortality, major adverse cardiovascular events, and heart failure.
Results: During hospital stay, 26 patients died and 288 suffered major morbidity. After 3.6 years of follow-up, 56 patients had died, 105 had major adverse cardiovascular events, and 70 developed heart failure. Multivariate analysis revealed every 1 mg·L−1 increase of high-sensitive C-reactive protein was associated with increased odds ratio for early mortality (odds ratio = 2.50, p = 0.002), major morbidity (odds ratio = 1.38, p = 0.02), and hazard ratio for midterm mortality (hazard ratio = 1.68, p = 0.03), major adverse cardiovascular events (hazard ratio = 1.48, p = 0.04), and heart failure (hazard ratio = 1.88, p = 0.01). Preoperative high-sensitive C-reactive protein > 2.5 mg·L−1 predicted higher risks of early (hazard ratio = 2.69, p = 0.02) and midterm mortality (hazard ratio = 1.92, p = 0.02), major morbidity (hazard ratio = 1.46, p = 0.004), major adverse cardiovascular events (hazard ratio = 2.06, p < 0.001), and heart failure (hazard ratio = 1.71, p = 0.03).
Conclusions: Elevated high-sensitive C-reactive protein (>2.5 mg·L−1) predicts poor early and midterm outcomes after coronary artery bypass.
RossR. Atherosclerosis—an inflammatory disease. N Engl J Med1999; 340: 115–126.
2.
DrakopoulouMToutouzasKStefanadiETsiamisETousoulisDStefanadisC. Association of inflammatory markers with angiographic severity and extent of coronary artery disease [Review]. Atherosclerosis2009; 206: 335–359.
3.
DaneshJWheelerJGHirschfieldGMEdaSEiriksdottirGRumleyA. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med2004; 350: 1387–1397.
4.
ZebrackJSAndersonJLMaycockCAHorneBDBairTLMuhlesteinJB. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol2002; 89: 145–149.
5.
YinWHChenJWJenHLChiangMCHuangWPFengAN. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J2004; 147: 931–938.
6.
ParkDWLeeCWYunSCKimYHHongMKKimJJ. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart2007; 93: 1087–1092.
7.
ParolariACameraMAlamanniFNaliatoMPolvaniGLAgrifoglioM. Systemic inflammation after on-pump and off-pump coronary bypass surgery: a one-month follow-up. Ann Thorac Surg2007; 84: 823–828.
8.
van StratenAHSoliman HamadMAvan ZundertAJMartensEJSchönbergerJPde WolfAM. Preoperative C-reactive protein levels to predict early and late mortalities after coronary artery bypass surgery: eight years of follow-up. J Thorac Cardiovasc Surg2009; 138: 954–958.
9.
BalciunasMBagdonaiteLSamalaviciusRGriskeviciusLVuylstekeA. Pre-operative high sensitive C-reactive protein predicts cardiovascular events after coronary artery bypass grafting surgery: a prospective observational study. Ann Card Anaesth2009; 12: 127–132.
10.
PalmeriniTMarzocchiAMarrozziniCReggianiLBSaviniCMarinelliG. Preoperative C-reactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis. Eur J Cardiothorac Surg2007; 31: 685–690.
11.
KangasniemiOPBiancariFLuukkonenJVuorisaloSSattaJPokelaR. Preoperative C-reactive protein is predictive of long-term outcome after coronary artery bypass surgery. Eur J Cardiothorac Surg2006; 29: 983–985.
12.
CappabiancaGPaparellaDVisicchioGCaponeGLionettiGNumisF. Preoperative C-reactive protein predicts mid-term outcome after cardiac surgery. Ann Thorac Surg2006; 82: 2170–2178.
13.
BiancariFLahtinenJLepojarviSRainioPSalmelaEPokelaR. Preoperative C-reactive protein and outcome after coronary artery bypass surgery. Ann Thorac Surg2003; 76: 2007–2012.
14.
GaudinoMNassoGAndreottiFMinnitiGIacovielloLDonatiM. Preoperative C-reactive protein level and outcome following coronary surgery. Eur J Cardiothorac Surg2002; 22: 521–526.
15.
KimDHShimJKHongSWChoKRKangSYKwakYL. Predictive value of C-reactive protein for major postoperative complications following off-pump coronary artery bypass surgery: prospective and observational trial. Circ J2009; 73: 872–877.
16.
RobertsWLSedrickRMoultonLSpencerARifaiN. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem2000; 46: 461–468.
17.
LiYZhengZHuS. Early and long-term outcomes in the elderly: comparison between off-pump and on-pump techniques in 1191 patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg2008; 136: 657–664.
18.
ShahianDMO'BrienSMFilardoGFerrarisVAHaanCKRichJB. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1—coronary artery bypass grafting surgery. Ann Thorac Surg2009; 88: S2–S22.
19.
PearsonTAMensahGAAlexanderRWAndersonJLCannonRO3rdCriquiM. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003; 107: 499–511.
20.
RidkerPMCushmanMStampferMJTracyRPHennekensCH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997; 336: 973–979.
21.
RidkerPMCannonCPMorrowDRifaiNRoseLMMcCabeCH. C-reactive protein levels and outcomes after statin therapy. N Engl J Med2005; 352: 20–28.
22.
van der HarstPVoorsAAVolbedaMBuikemaHvan VeldhuisenDJvan GilstWH. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol2006; 97: 1697–1701.
